PUBLISHER: DataM Intelligence | PRODUCT CODE: 1373374
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1373374
A biomaterial is a substance that has been engineered to interact with biological systems for a medical purpose, either a therapeutic or a diagnostic test. Biomaterials can be created in the lab using a number of chemical techniques using metallic or polymeric components, ceramics, or composite materials, and biomaterials can also be obtained from nature.
Orthopedic biomaterials are used from temporary implants to fix bone to permanent implant materials and bioabsorbable implants. Common orthopedic biomaterials include calcium phosphate cements, bioactive glasses, polymers, metals, and composites.
The increasing number of orthopedic surgeries acts as a significant driver for market growth. In orthopedic surgeries, biomaterials can be utilized to replace or regenerate damaged or diseased tissues in order to improve their physiological performance.
For instance, the American Joint Replacement Registry (AJRR), published its 2022 annual report that demonstrates an overall cumulative procedural growth of 14% compared to the previous year and includes over 2.8 million hip and knee procedures since 2012 from over 1,250 hospitals, ambulatory surgery centers, and private practice groups. Hence, the demand for biomaterials increases that can be used in orthopedic surgeries.
Also, according to the WHO, approximately 20-50 million people get non-fatal injuries because of road casualties yearly. Likewise, according to the CDC, roughly 2,885,545 ambulatory cases were reported with non-fatal injuries requiring surgery in 2020. Thus, due to these injuries, the use of orthopedic biomaterials increased which help to boost the market.
Furthermore, significant growth drivers such as the growing number of cases of chronic diseases like rheumatoid arthritis, and osteoarthritis, and, product launches are expected to drive the market in the forecast period.
Pre-market approval and lengthy clinical trials are among the strict regulatory criteria that apply to the orthopedic biomaterial market. These expensive and time-consuming regulatory procedures raise the overall cost of development while delaying the release of novel biomaterial products into the market. The above factors are expected to hamper the market growth.
The global orthopedic biomaterials market is segmented based on material type, application, end users and region.
Calcium phosphate cement is a bioactive and biodegradable grafting material in the form of powder and liquid. Calcium phosphate cements are expected to hold the largest market share over the period forecast owing to increasing new orthopedic biomaterial launches and technical advancements.
For instance, in July 2022, Curasan AG launched the CERASORB CPC (Calcium Phosphate Cement) Bone Void Fillers for maxillofacial, orthopedic, and trauma surgery. CERASORB CPC is a synthetic, biocompatible, osteoconductive, and bioresorbable mineral bone cement composed of calcium and phosphate salts finely dispersed in a biocompatible oil.
Additionally, in May 2022, Granulab (M) Sdn Bhd launched Malaysia's first halal-certified synthetic bone cement called Prosteomax. It is an innovative calcium phosphate-based synthetic bone cement that has been certified halal by the Islamic Development Department Malaysia.
The global orthopedic biomaterials market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of orthopedic surgeries, and product launches, this trend is anticipated to continue throughout the forecast period.
For instance, in April 2023, Abyrx, Inc. received U.S. FDA clearances for the MONTAGE Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement. MONTAGE is a hand-moldable, hardening putty that, within minutes after mixing, develops bone-like characteristics and offers a unique intraoperative application.
Additionally, in February 2022, Orthofix Medical Inc. launched the Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. Opus BA can be used to fill skeletal system gaps or holes that are not essential to the stability of the bony structure.
The COVID-19 pandemic has had a significant impact on the global orthopedic biomaterials market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, biomaterial launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the orthopedic biomaterials market is expected to be moderately affected over the forecast period.
The major global players in the market include: Stryker Corporation, Koninklijke DSM N.V., Evonik Industries AG, Globus Medical, Zimmer Biomet Holdings Inc., Medbone, Invibio Ltd., CAM Bioceramics B.V., Exactech Inc., DePuy Synthes among others.
The global orthopedic biomaterials market report would provide approximately 61 tables, 63 figures, and 185 Pages.